Jefferies Upgrades Humana to Buy on Medicare Advantage Diversification
Jefferies has upgraded Humana's stock rating to Buy, citing the company's strategic diversification in its Medicare Advantage product portfolio. This shift is expected to drive significant earnings growth in 2026 and 2027. The analysis is based on detailed scrutiny of Humana's current contracts and anticipated market performance, highlighting the firm's strengthened position in the Medicare Advantage market segment.